letrozole has been researched along with fulvestrant in 93 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (4.30) | 18.2507 |
| 2000's | 25 (26.88) | 29.6817 |
| 2010's | 46 (49.46) | 24.3611 |
| 2020's | 18 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, JZ; Khan, MZI; Nazli, A; Uzair, M | 1 |
| Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Brodie, AM; Grigoryev, DN; Long, BJ; Thiantanawat, A; Tilghman, SL; Yue, W | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Mokbel, K | 1 |
| Tominaga, T | 1 |
| Brodie, AM; Jelovac, D; Long, BJ; Thiantanawat, A | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Eckhardt, S | 1 |
| Tobias, JS | 1 |
| Harwood, KV | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Macedo, L; Sabnis, G; Tilghman, S | 1 |
| Kaplow, R | 1 |
| Dodwell, D; Vergote, I | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G | 1 |
| Connell, BJ; Cribb, AE; Legge, C; Saleh, TM | 1 |
| Chagin, AS; Chrysis, D; Ritzen, EM; Sävendahl, L; Takigawa, M | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Brodie, A; Jelovac, D; Sabnis, G | 1 |
| Croxatto, HB; Garfield, R; Ortiz, ME; Ortiz, RE; Zepeda, AJ | 1 |
| Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Bütow, A; Fester, L; Huber, C; Jarry, H; Prange-Kiel, J; Rune, GM; von Lossow, R; Zhou, L | 1 |
| Bonthuis, P; Ding, A; Park, JH; Rais, S; Rissman, EF | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Dieni, C; Frondaroli, A; Grassi, S; Pettorossi, VE; Scarduzio, M | 1 |
| Bocchinfuso, W; Conaway, M; Fan, P; Korach, KS; Li, Y; Liu, G; Santen, R; Wang, H; Wang, JP; Yue, W; Zhang, N | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA | 1 |
| Bois, C; Bouraïma-Lelong, H; Carreau, S; Delalande, C; Durand, P | 1 |
| Chen, S; Reddy, K; Smith, D; Wang, X; Wong, C | 1 |
| Li, W; Tang, L; Wu, L; Xiong, Y; Zhou, X | 1 |
| Berger, T; Conley, AJ; Hovey, RC; Roser, JF; Van Klompenberg, M | 1 |
| Dowsett, M; Gao, Q; Isacke, CM; Mackay, A; Martin, LA; Morandi, A; Pancholi, S; Plaza-Menacho, I; Robertson, D; Zvelebil, M | 1 |
| Mehta, A; Tripathy, D | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Aktas, B; Anton, A; Carrasco, E; De la Haba-Rodriguez, JR; Garcia-Saenz, JÁ; Gil, M; Guerrero, A; Liedtke, C; Loibl, S; Margeli, M; Martín, M; Martinez, N; Mehta, K; Morales, S; Muñoz, M; Ramos, M; Schoenegg, W; von Minckwitz, G; Wachsmann, G | 1 |
| Berger, T; Conley, AJ; Katleba, KD; Legacki, EL | 1 |
| Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y | 1 |
| Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Tamura, K | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Niraula, S; Ocana, A | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Endo, T; Hasegawa, K; Higashi, Y; Kamiya, A; Kaneko, J; Kondo, I; Maejima, S; Takatsuno, Y | 1 |
| Cappelletti, MR; Corona, SP; Cretella, D; Dester, M; Generali, D; Gobbi, A; Petronini, PG; Ravelli, A; Zanotti, L | 1 |
| Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Kim, ES; Scott, LJ | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Freedman, RA; Tolaney, SM | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC | 1 |
| Chen, L; Ding, W; Li, Z; Ruan, G; Tu, C; Wang, C | 1 |
| Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Huang Bartlett, C; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Slamon, DJ; Turner, NC | 1 |
| Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S | 1 |
| Band, J; Darden, C; Davis, K; Iyer, S; McSorley, D; Mitra, D | 1 |
| Darbre, PD; Williams, GP | 1 |
| Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L | 1 |
| Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y | 1 |
| Berger, T; Kucera, H; Sidhu, P; Tang, S | 1 |
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
| Yardley, DA | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J | 1 |
| Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML | 1 |
| Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mukai, H; Muramatsu, Y; Ohno, S; Ohtani, S; Rai, Y; Shimizu, C; Toi, M; Umeyama, Y | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L | 1 |
| Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil-Gil, M; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-de Dueñas, E; Pérez-García, JM; Ruíz-Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P | 1 |
| Fu, F; Guindy, M; Kano, J; Ma, J | 1 |
| Jacobson, A | 1 |
| Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E | 1 |
| Adam, JP; Chabot, I; David, MÈ; Lessard-Hurtubise, R; Marineau, A; St-Pierre, C | 1 |
| Attwood, K; Edge, S; Hamilton, D; Knudsen, ES; Levine, E; O'Connor, T; Schultz, E; Witkiewicz, AK | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Choong, GM; Ferre, RAL; Giridhar, KV; Goetz, MP; Haddad, TC; Hobday, TJ; Liddell, S; Liu, MC; O'Sullivan, CC; Peethambaram, PP; Ruddy, KJ | 1 |
| Acconcia, F | 1 |
| Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Carañana, V; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil Gil, MJ; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-De Dueñas, E; Mina, L; Pérez-García, JM; Ruiz Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P | 1 |
| Ademuyiwa, FO; Clifton, K; Dai, C; Davis, AA; Dong, X; Du, P; Frith, A; Haas, B; Hernandez-Aya, LF; Jia, S; King, BL; Krishnamurthy, J; Luo, J; Luo, SJ; Ma, CX; Peterson, LL; Rearden, TP; Rigden, C; Summa, T; Suresh, R; Tan, L; Tandra, PK; Thomas, S; Wang, X; Weilbaecher, K; Zheng, T; Zhou, K | 1 |
31 review(s) available for letrozole and fulvestrant
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen | 2022 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Therapeutic observations in MCF-7 aromatase xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Nitriles; Receptors, Estrogen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Letrozole; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Transcriptional Activation; Triazoles | 2012 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States | 2015 |
Development of cell-cycle checkpoint therapy for solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Staging; Nitriles; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2015 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
CDK4/6 inhibitors in HER2-positive breast cancer.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Nitriles; Protein Kinase Inhibitors; Receptor, ErbB-2; Triazoles | 2017 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies; Thrombocytopenia | 2021 |
10 trial(s) available for letrozole and fulvestrant
| Article | Year |
|---|---|
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Germany; Hormones; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Spain; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor A | 2015 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Quality of Life; Viscera | 2018 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Japan; Letrozole; Middle Aged; Piperazines; Postmenopause; Premenopause; Progression-Free Survival; Pyridines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2 | 2021 |
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Pulmonary Embolism; Receptor, ErbB-2; Receptors, Estrogen; Venous Thromboembolism | 2023 |
52 other study(ies) available for letrozole and fulvestrant
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cells, Cultured; Choriocarcinoma; DNA Primers; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblasts; Fulvestrant; Humans; Letrozole; Microsomes; Nitriles; Placenta; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 1998 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2002 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Estrogen synthesis in the central nucleus of the amygdala following middle cerebral artery occlusion: role in modulating neurotransmission.
Topics: Amygdala; Animals; Aromatase Inhibitors; Autonomic Nervous System; Blood Pressure; Brain Chemistry; Estradiol; Estrogen Antagonists; Estrogens; Excitatory Amino Acid Antagonists; Fulvestrant; Heart Rate; Infarction, Middle Cerebral Artery; Injections, Intraventricular; Letrozole; Male; Microdialysis; Nitriles; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Synaptic Transmission; Testosterone; Triazoles | 2005 |
Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Cell Division; Cell Line; Chondrocytes; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Letrozole; Metatarsal Bones; Nitriles; Rats; Triazoles | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Progesterone, but not luteal estrogen, is required for the establishment of pregnancy in the new world monkey Cebus apella.
Topics: Animals; Aromatase Inhibitors; Cebus; Embryo Implantation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Letrozole; Luteal Phase; Male; Mifepristone; Nitriles; Pregnancy; Pregnancy Rate; Pregnancy, Animal; Progesterone; Triazoles | 2007 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus.
Topics: Animals; Animals, Newborn; Aromatase Inhibitors; Cells, Cultured; Cholesterol; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Hippocampus; In Vitro Techniques; Letrozole; Male; Microfilament Proteins; Nerve Tissue Proteins; Neurons; Nitriles; Phosphoproteins; Rats; Rats, Wistar; Synapses; Synaptophysin; Triazoles | 2009 |
Androgen- and estrogen-independent regulation of copulatory behavior following castration in male B6D2F1 mice.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Aromatase; Aromatase Inhibitors; Copulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flutamide; Fulvestrant; Letrozole; Male; Mating Preference, Animal; Mice; Nitriles; Orchiectomy; Preoptic Area; Receptors, Androgen; RNA, Messenger; Septal Nuclei; Triazoles | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Long-term potentiation in the rat medial vestibular nuclei depends on locally synthesized 17beta-estradiol.
Topics: Animals; Animals, Newborn; Aromatase Inhibitors; Bicuculline; Biophysics; Drug Interactions; Electric Stimulation; Estradiol; Estrogen Antagonists; Excitatory Amino Acid Antagonists; Fulvestrant; GABA Antagonists; In Vitro Techniques; Letrozole; Long-Term Potentiation; Male; Nitriles; Quinoxalines; Rats; Rats, Wistar; Triazoles; Valine; Vestibular Nuclei | 2009 |
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mice, Transgenic; Nitriles; Ovariectomy; Triazoles; Wnt1 Protein | 2010 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays | 2011 |
17β-Estradiol regulates cyclin A1 and cyclin B1 gene expression in adult rat seminiferous tubules.
Topics: Animals; Aromatase Inhibitors; Cyclin A1; Cyclin B1; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression; Letrozole; Male; Nitriles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Seminiferous Tubules; Spermatogenesis; Triazoles | 2012 |
The chondroprotective effects of dehydroepiandrosterone probably exerted by its conversion to estradiol.
Topics: Adjuvants, Immunologic; Animals; Aromatase Inhibitors; Cartilage; Cells, Cultured; Chondrocytes; Dehydroepiandrosterone; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Letrozole; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Nitriles; Osteoarthritis; Rabbits; Tissue Inhibitor of Metalloproteinase-1; Triazoles | 2013 |
Increased testicular Sertoli cell population induced by an estrogen receptor antagonist.
Topics: Animals; Aromatase; Cell Count; Estradiol; Estrogen Antagonists; Fulvestrant; Letrozole; Male; Nitriles; Pituitary Hormones; Receptors, Estrogen; Sertoli Cells; Steroids; Sus scrofa; Triazoles | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor; Humans; Kaplan-Meier Estimate; Letrozole; MCF-7 Cells; Middle Aged; Nitriles; Oligonucleotide Array Sequence Analysis; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Triazoles | 2013 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
Steroid regulation of early postnatal development in the corpus epididymidis of pigs.
Topics: Androgen Receptor Antagonists; Animals; Aromatase; Aromatase Inhibitors; Blood-Testis Barrier; Epididymis; Estradiol; Estrogen Receptor Antagonists; Flutamide; Fulvestrant; Letrozole; Male; Microscopy, Electron, Transmission; Nitriles; Protein Isoforms; Receptors, Androgen; Receptors, Estrogen; Receptors, G-Protein-Coupled; Sexual Development; Signal Transduction; Sus scrofa; Tight Junctions; Triazoles | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
[Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Lung Neoplasms; Nitriles; Treatment Outcome; Triazoles | 2016 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles | 2017 |
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Medical Oncology; Nitriles; Piperazines; Pyridines; Triazoles | 2017 |
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Patient Satisfaction; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Surveys and Questionnaires; Treatment Outcome | 2019 |
Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells.
Topics: Aromatase; Breast; Cell Line, Tumor; Cell Proliferation; Endocrine Disruptors; Estradiol; Female; Fulvestrant; Humans; Letrozole; Receptors, Estrogen; RNA, Messenger; Testosterone | 2019 |
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Pyridines; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Are testicular cortisol and WISP2 involved in estrogen-regulated Sertoli cell proliferation?
Topics: Animals; CCN Intercellular Signaling Proteins; Cell Proliferation; Dexamethasone; Estrogens; Fulvestrant; Gene Expression; Hydrocortisone; Letrozole; Male; Sertoli Cells; Sex Differentiation; Spermatozoa; Swine; Testis | 2019 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Administration Schedule; Estrogens; Fatigue; Febrile Neutropenia; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Mucositis; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Thrombocytopenia | 2020 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase | 2020 |
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies | 2022 |
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Letrozole; Thiazoles | 2022 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Letrozole; Patient-Centered Care; Pharmacies; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Letrozole; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; TOR Serine-Threonine Kinases | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Genomics; Humans; Letrozole; Receptor, ErbB-2 | 2023 |